Condition: Urological Manifestations · Sponsor: Centre Hospitalier Intercommunal Robert Ballanger
any studies have shown the benefit of perioperative Oral Impact immunomodulation in gastrointestinal, ENT, gynecological and cardiac surgery. Studies in major Urological surgery are rare and not very contributory. The expected benefit is a reduction in postoperative complications and the average length of stay.
This description comes directly from the study's public registry record.
Serge Ndoko, MD · 01.49.36.70.41 · serge.ndoko@ght-gpne.fr
Sabrina Lassouani, MD · 01.49.36.70.41 · sabrina.lassouani-amara@ght-gpne.fr
Always discuss trial participation with your own doctor first.
| CHI Robert Ballanger | Aulnay-sous-Bois, France | Recruiting |
| CHI André Grégoire | Montreuil, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05520151